MorphoSys Announces Re-election of Supervisory Board Members

Dr. Gerald Moller Re-elected as Chairman of the Supervisory Board


MARTINSRIED, Germany, May 15, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today that at the Company's annual shareholder meeting on Wednesday, May 14, 2008, its shareholders confirmed the reappointment of Dr. Gerald Moller, Dr. Daniel Camus, Dr. Metin Colpan and Dr. Geoffrey N. Vernon to the Supervisory Board. Dr. Moller was reappointed as Chairman of the Supervisory Board.

In addition to the confirmation of the appointments to the Supervisory Board, all other management proposals put to vote were passed at the meeting, which took place in Munich.

As part of the shareholder assembly agenda, the shareholders approved a three-for-one split of the Company's common stock.

"We are pleased to announce the re-election of all of our long-term members of the Supervisory board and look forward to continue working with them," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Their commitment and enormous contributions to MorphoSys's successful development over the last several years have been extremely valuable for the Company."

About MorphoSys:

MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/

HuCAL(r) and HuCAL GOLD(r) are registered trademarks of MorphoSys AG

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

http://hugin.info/130295/R/1219635/256083.pdf



            

Contact Data